{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:14Z","timestamp":1792787834388,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"University of Oulu","id":[{"id":"https:\/\/ror.org\/03yj89h83","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-05083-2","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:44:25Z","timestamp":1782816265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of real-life visual outcomes and treatment efficacy of diabetic macular edema in patients with type 2 diabetes"],"prefix":"10.1186","volume":"26","author":[{"given":"Annika","family":"Konttinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joonas","family":"Wirkkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Kubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi","family":"Ohtonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5454-5602","authenticated-orcid":false,"given":"Nina","family":"Hautala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"5083_CR1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"5083_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556\u201364.","journal-title":"Diabetes Care"},{"key":"5083_CR3","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham Y-C, Yu M, et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. Ophthalmology. 2021;128:1580\u201391.","journal-title":"Ophthalmology"},{"key":"5083_CR4","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","volume":"132","author":"R Varma","year":"2014","unstructured":"Varma R, Bressler NM, Doan QV, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132:1334\u201340.","journal-title":"JAMA Ophthalmol"},{"key":"5083_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/aos.12278","volume":"92","author":"N Hautala","year":"2014","unstructured":"Hautala N, Aikkila R, Korpelainen J, Keskitalo A, Kurikka A, Falck A, Bloigu R, Alanko H. Marked reductions in visual impairment due to diabetic retinopathy achieved by efficient screening and timely treatment. Acta Ophthalmol. 2014;92:582\u20137.","journal-title":"Acta Ophthalmol"},{"key":"5083_CR6","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.2337\/dc21-2369","volume":"45","author":"PKM Purola","year":"2022","unstructured":"Purola PKM, Ojamo MUI, Gissler M, Uusitalo HMT. Changes in Visual Impairment due to Diabetic Retinopathy During 1980\u20132019 Based on Nationwide Register Data. Diabetes Care. 2022;45:2020\u20137.","journal-title":"Diabetes Care"},{"key":"5083_CR7","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","volume":"122","author":"A Das","year":"2015","unstructured":"Das A, McGuire PG, Rangasamy S. Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. Ophthalmology. 2015;122:1375\u201394.","journal-title":"Ophthalmology"},{"key":"5083_CR8","first-page":"28","volume":"7","author":"K Miller","year":"2018","unstructured":"Miller K, Fortun JA. Diabetic Macular Edema: Current Understanding, Pharmacologic Treatment Options, and Developing Therapies. Asia Pac J Ophthalmol (Phila). 2018;7:28\u201335.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"5083_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2337\/dc13-2002","volume":"37","author":"R Sim\u00f3","year":"2014","unstructured":"Sim\u00f3 R, Sundstrom JM, Antonetti DA. Ocular Anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care. 2014;37:893\u20139.","journal-title":"Diabetes Care"},{"key":"5083_CR10","doi-asserted-by":"publisher","first-page":"632307","DOI":"10.1155\/2014\/632307","volume":"2014","author":"FR Stefanini","year":"2014","unstructured":"Stefanini FR, Badar\u00f3 E, Falabella P, Koss M, Farah ME, Maia M. Anti-VEGF for the management of diabetic macular edema. J Immunol Res. 2014;2014:632307.","journal-title":"J Immunol Res"},{"key":"5083_CR11","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","volume":"32","author":"S Fogli","year":"2018","unstructured":"Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye. 2018;32:1010\u201320.","journal-title":"Eye"},{"key":"5083_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11892-019-1188-4","volume":"19","author":"EJ Kim","year":"2019","unstructured":"Kim EJ, Lin WV, Rodriguez SM, Chen A, Loya A, Weng CY. Treatment of Diabetic Macular Edema. Curr Diab Rep. 2019;19:68.","journal-title":"Curr Diab Rep"},{"issue":"2","key":"5083_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00417-023-06269-w","volume":"262","author":"J Choi","year":"2024","unstructured":"Choi J, Kim SJ, Kang SW, Hwang S, Son KY. Biomarkers determining treatment interval of diabetic macular edema after initial resolution by anti-vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 2024;262(2):421\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5083_CR14","first-page":"893","volume-title":"[Update on Current Care Guideline: Diabetic retinopathy]","author":"P Summanen","year":"2015","unstructured":"Summanen P, Kallioniemi V, Komulainen J, Eriksson L, Forsvik H, Hietala K, Tulokas S, Von Wendt G. [Update on Current Care Guideline: Diabetic retinopathy]. Volume 131. P\u00e4ivitystiivistelm\u00e4: Duodecim; 2015. pp. 893\u20134."},{"key":"5083_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, Jonas J, Larsen M, Tadayoni R, Loewenstein A. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185\u2013222.","journal-title":"Ophthalmologica"},{"key":"5083_CR16","unstructured":"(2024) Diabetic retinopathy: management and monitoring. National Institute for Health and Care Excellence (NICE), London."},{"key":"5083_CR17","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016;123:1351\u20139.","journal-title":"Ophthalmology"},{"key":"5083_CR18","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier JS, Korobelnik J-F, Brown DM, et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology. 2016;123:2376\u201385.","journal-title":"Ophthalmology"},{"key":"5083_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamaophthalmol.2016.4912","volume":"135","author":"CC Wykoff","year":"2017","unstructured":"Wykoff CC, Marcus DM, Midena E, et al. Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials. JAMA Ophthalmol. 2017;135:107\u201314.","journal-title":"JAMA Ophthalmol"},{"key":"5083_CR20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","volume":"118","author":"P Mitchell","year":"2011","unstructured":"Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615\u201325.","journal-title":"Ophthalmology"},{"key":"5083_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa2204225","volume":"387","author":"CD Jhaveri","year":"2022","unstructured":"Jhaveri CD, Glassman AR, Ferris FL 3rd, et al. Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med. 2022;387:692\u2013703.","journal-title":"N Engl J Med"},{"key":"5083_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1001\/jamaophthalmol.2022.6142","volume":"141","author":"DW Hutton","year":"2023","unstructured":"Hutton DW, Glassman AR, Liu D, Sun JK, Retina Network DRCR. Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. JAMA Ophthalmol. 2023;141:268\u201374.","journal-title":"JAMA Ophthalmol"},{"key":"5083_CR23","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.ophtha.2024.01.037","volume":"131","author":"CD Jhaveri","year":"2024","unstructured":"Jhaveri CD, Liu D, Maguire MG, et al. Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20\/40. Ophthalmology. 2024;131:967\u201374.","journal-title":"Ophthalmology"},{"key":"5083_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164782","author":"C-C Ma","year":"2024","unstructured":"Ma C-C, Chen P-H, Hsieh Y-H. Optimizing Diabetic Macular Edema Treatment: A Meta-Analysis of Subthreshold Micropulse Laser and Anti-Vascular Endothelial Growth Factor Combination Therapy. J Clin Med Res. 2024. https:\/\/doi.org\/10.3390\/jcm13164782.","journal-title":"J Clin Med Res"},{"key":"5083_CR25","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.survophthal.2024.07.006","volume":"69","author":"S Vujosevic","year":"2024","unstructured":"Vujosevic S, Lupidi M, Donati S, Astarita C, Gallinaro V, Pilotto E. Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration. Surv Ophthalmol. 2024;69:870\u201381.","journal-title":"Surv Ophthalmol"},{"key":"5083_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/jamaophthalmol.2019.6035","volume":"138","author":"AR Glassman","year":"2020","unstructured":"Glassman AR, Baker CW, Beaulieu WT, Bressler NM, Punjabi OS, Stockdale CR, Wykoff CC, Jampol LM, Sun JK, DRCR Retina Network. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020;138:341\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"5083_CR27","doi-asserted-by":"publisher","first-page":"100226","DOI":"10.1016\/j.xops.2022.100226","volume":"3","author":"A Torjani","year":"2023","unstructured":"Torjani A, Mahmoudzadeh R, Salabati M, Cai L, Hsu J, Garg S, Ho AC, Yonekawa Y, Kuriyan AE, Starr MR. Factors Associated with Fluctuations in Central Subfield Thickness in Patients with Diabetic Macular Edema Using Diabetic Retinopathy Clinical Research Protocols T and V. Ophthalmol Sci. 2023;3:100226.","journal-title":"Ophthalmol Sci"},{"key":"5083_CR28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2021.06.030","volume":"232","author":"MR Starr","year":"2021","unstructured":"Starr MR, Salabati M, Mahmoudzadeh R, Patel LG, Ammar MJ, Hsu J, Garg S, Ho AC, Kuriyan AE. Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting. Am J Ophthalmol. 2021;232:90\u20137.","journal-title":"Am J Ophthalmol"},{"key":"5083_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3928\/23258160-20221122-01","volume":"54","author":"NS Patil","year":"2023","unstructured":"Patil NS, Mihalache A, Dhoot AS, Popovic MM, Muni RH, Kertes PJ. The Impact of Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Systematic Review. Ophthalmic Surg Lasers Imaging Retina. 2023;54:50\u20138.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"5083_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/1573399811309030002","volume":"9","author":"K Kamoi","year":"2013","unstructured":"Kamoi K, Takeda K, Hashimoto K, Tanaka R, Okuyama S. Identifying risk factors for clinically significant diabetic macula edema in patients with type 2 diabetes mellitus. Curr Diabetes Rev. 2013;9:209\u201317.","journal-title":"Curr Diabetes Rev"},{"key":"5083_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001325","author":"R Rajalakshmi","year":"2020","unstructured":"Rajalakshmi R, Shanthi Rani CS, Venkatesan U, Unnikrishnan R, Anjana RM, Jeba Rani S, UmaSankari G, Sivaprasad S, Raman R, Mohan V. Correlation between markers of renal function and sight-threatening diabetic retinopathy in type 2 diabetes: a longitudinal study in an Indian clinic population. BMJ Open Diabetes Res Care. 2020. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001325.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"5083_CR32","doi-asserted-by":"publisher","first-page":"100557","DOI":"10.1016\/j.xops.2024.100557","volume":"4","author":"R Haliyur","year":"2024","unstructured":"Haliyur R, Marwah S, Mittal S, Stein JD, Shah AR, SOURCE Consortium. Demographic and Metabolic Risk Factors Associated with Development of Diabetic Macular Edema among Persons with Diabetes Mellitus. Ophthalmol Sci. 2024;4:100557.","journal-title":"Ophthalmol Sci"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05083-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05083-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05083-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:27:26Z","timestamp":1789946846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-05083-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5083"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05083-2","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Oulu University Hospital Research Ethics Committee (approval no. 175\/2016) on June 24, 2016. All participants provided written informed consent prior to participating.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"580"}}